Evaxion A/S (EVAX) Competitors $3.05 +0.02 (+0.66%) Closing price 03:59 PM EasternExtended Trading$3.04 -0.01 (-0.49%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVAX vs. AIMD, LEXX, BLRX, ATHA, ADAP, EDSA, IMNN, MTVA, NEUP, and PRPHShould you be buying Evaxion A/S stock or one of its competitors? The main competitors of Evaxion A/S include Ainos (AIMD), Lexaria Bioscience (LEXX), BioLineRx (BLRX), Athira Pharma (ATHA), Adaptimmune Therapeutics (ADAP), Edesa Biotech (EDSA), Imunon (IMNN), MetaVia (MTVA), Neuphoria Therapeutics (NEUP), and ProPhase Labs (PRPH). These companies are all part of the "pharmaceutical products" industry. Evaxion A/S vs. Its Competitors Ainos Lexaria Bioscience BioLineRx Athira Pharma Adaptimmune Therapeutics Edesa Biotech Imunon MetaVia Neuphoria Therapeutics ProPhase Labs Ainos (NASDAQ:AIMD) and Evaxion A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings. Do insiders & institutionals hold more shares of AIMD or EVAX? 11.0% of Evaxion A/S shares are owned by institutional investors. 10.4% of Ainos shares are owned by insiders. Comparatively, 41.6% of Evaxion A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the media refer more to AIMD or EVAX? In the previous week, Evaxion A/S had 1 more articles in the media than Ainos. MarketBeat recorded 2 mentions for Evaxion A/S and 1 mentions for Ainos. Ainos' average media sentiment score of 1.68 beat Evaxion A/S's score of 0.94 indicating that Ainos is being referred to more favorably in the media. Company Overall Sentiment Ainos Very Positive Evaxion A/S Positive Which has stronger valuation and earnings, AIMD or EVAX? Evaxion A/S has higher revenue and earnings than Ainos. Evaxion A/S is trading at a lower price-to-earnings ratio than Ainos, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAinos$20K927.34-$14.86M-$4.99-0.80Evaxion A/S$3.34M1.28-$10.57M-$1.32-2.31 Is AIMD or EVAX more profitable? Ainos has a net margin of 0.00% compared to Evaxion A/S's net margin of -316.03%. Ainos' return on equity of -108.25% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets AinosN/A -108.25% -56.94% Evaxion A/S -316.03%-319.52%-63.56% Which has more volatility and risk, AIMD or EVAX? Ainos has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Comparatively, Evaxion A/S has a beta of 0.13, meaning that its share price is 87% less volatile than the S&P 500. Do analysts prefer AIMD or EVAX? Evaxion A/S has a consensus price target of $10.00, indicating a potential upside of 227.87%. Given Evaxion A/S's stronger consensus rating and higher probable upside, analysts clearly believe Evaxion A/S is more favorable than Ainos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Evaxion A/S 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryEvaxion A/S beats Ainos on 9 of the 16 factors compared between the two stocks. Get Evaxion A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for EVAX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVAX vs. The Competition Export to ExcelMetricEvaxion A/SMEDICAL INFO SYS IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.27M$2.06B$5.76B$9.84BDividend YieldN/AN/A3.95%4.02%P/E Ratio-2.3137.5831.3126.60Price / Sales1.2813.21461.30121.37Price / CashN/A52.2937.7659.36Price / Book0.696.5910.026.67Net Income-$10.57M-$63.67M$3.27B$265.59M7 Day Performance-1.61%3.23%3.17%3.42%1 Month Performance4.10%0.62%4.34%1.09%1 Year Performance-79.73%28.23%44.11%23.85% Evaxion A/S Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVAXEvaxion A/S2.3448 of 5 stars$3.05+0.7%$10.00+227.9%-81.5%$4.27M$3.34M-2.3160Gap UpAIMDAinos1.0502 of 5 stars$3.35-3.2%N/A+16.2%$16.12M$20K-0.6740Positive NewsLEXXLexaria Bioscience3.7782 of 5 stars$0.84+2.1%$4.00+378.2%-69.1%$16.03M$460K-1.257News CoverageBLRXBioLineRx3.4121 of 5 stars$3.83+3.2%$26.00+578.9%-86.8%$15.81M$28.94M-0.4440Gap UpATHAAthira Pharma3.7498 of 5 stars$0.39-1.9%$0.50+27.3%-87.9%$15.80MN/A-0.2540Positive NewsADAPAdaptimmune Therapeutics1.9691 of 5 stars$0.07+17.6%$1.35+1,831.0%-95.2%$15.77M$65.09M-0.11490High Trading VolumeEDSAEdesa Biotech1.8031 of 5 stars$2.31+3.4%$5.00+116.9%-49.0%$15.73MN/A-1.7520Gap DownHigh Trading VolumeIMNNImunon1.8939 of 5 stars$6.48+1.3%$232.50+3,488.0%-65.2%$15.62M$500K-0.5030Positive NewsGap UpMTVAMetaVia2.0849 of 5 stars$0.65+1.7%$7.50+1,052.8%N/A$15.49MN/A0.008Gap UpNEUPNeuphoria Therapeutics1.8946 of 5 stars$7.79-3.8%$21.00+169.6%N/A$15.23M$10K0.00N/ANews CoverageAnalyst ForecastAnalyst RevisionPRPHProPhase Labs1.3098 of 5 stars$0.33-4.4%N/A-86.0%$14.51M$6.77M-0.27130Positive News Related Companies and Tools Related Companies Ainos Competitors Lexaria Bioscience Competitors BioLineRx Competitors Athira Pharma Competitors Adaptimmune Therapeutics Competitors Edesa Biotech Competitors Imunon Competitors MetaVia Competitors Neuphoria Therapeutics Competitors ProPhase Labs Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVAX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion A/S - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.